Skip to Main Content

A highly anticipated clinical trial combining two immunotherapy drugs failed to delay tumor growth in patients with newly diagnosed lung cancer, sending AstraZeneca sharply lower Thursday.

The negative results from the so-called MYSTIC study are a stinging setback to AstraZeneca’s ambition to leapfrog over its cancer immunotherapy rivals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • I solved the cancer problem years ago. Cancer could be cured and/or prevented
    by combined gene therapy and eye drops with dorzolamide. Other approaches
    with toxic drugs are deliberate fraud or innocent mistakes.
    Michael I. Lerman, M.D., Ph.D.
    Cancer causing Genes Expert,
    Laboratory of Immunobilogy, NCI, USA, 1980-2008,
    Board Member, Affina Biotechnologies, Inc., USA, present
    Email: [email protected]

Comments are closed.